NO20034031L - Substituted pyrazole and thiazole pyrimidines - Google Patents
Substituted pyrazole and thiazole pyrimidinesInfo
- Publication number
- NO20034031L NO20034031L NO20034031A NO20034031A NO20034031L NO 20034031 L NO20034031 L NO 20034031L NO 20034031 A NO20034031 A NO 20034031A NO 20034031 A NO20034031 A NO 20034031A NO 20034031 L NO20034031 L NO 20034031L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- diseases
- disease
- treatment
- tinnitus
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- UVRHPZOOCXESOY-UHFFFAOYSA-N pyrimidine;1,3-thiazole Chemical class C1=CSC=N1.C1=CN=CN=C1 UVRHPZOOCXESOY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000025157 Oral disease Diseases 0.000 abstract 2
- 208000009205 Tinnitus Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000030194 mouth disease Diseases 0.000 abstract 2
- 231100000886 tinnitus Toxicity 0.000 abstract 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 abstract 1
- 206010065040 AIDS dementia complex Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028921 Neonatal anoxia Diseases 0.000 abstract 1
- 206010028923 Neonatal asphyxia Diseases 0.000 abstract 1
- 206010050081 Neonatal hypoxia Diseases 0.000 abstract 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 208000033300 perinatal asphyxia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Det beskrives substituerte pyrazolopyrimidiner og tiazolopyrimidiner med den generelle formel (IA), (IB) og (II). en fremgangsmåte for deres fremstilling, substansbiblioteker inneholdende forbindelsene, medikamenter inneholdende forbindelser samt anvendelsen av forbindelsene ved fremstilling av medikamenter for behandling av smerte, epilepsi, schizofreni, neurodegenerative sykdommer og særlig Alzheimers sykdom, Huntingtons sykdom og Parkinsons sykdom, for behandling av cerebral ischemi og infarkter, psykoser forårsaket av økede aminosyrenivåer, cerebralt ødem, tilstander forårsaket av en under tilførsel til sentralnervesystemet, særlig ved hypoksi og spesielt nyfødt hypoksi og anoksi, for behandling av AIDS-relatert demens, encefalomyelitt, Tourettes syndrom, perinatal asfyksi, tinnitus, neuropatisk smerte, sykdommer i åndedrettssystemet, kreft, kardial arrytmi, irnmunlidelser og sykdommer, inflammatoriske tilstander og sykdommer, nyresvikt, søvnløshet, slag, tromboser, urininkontinens, diabetes, psoriasis, septisk sjokk, cerebralt trauma, laukom og/eller kongestiv hjertesvikt. Det beskrives videre farmasøytiske preparater inneholdende forbindelsene.Substituted pyrazolopyrimidines and thiazolopyrimidines of general formula (IA), (IB) and (II) are described. a process for their preparation, substance libraries containing the compounds, drugs containing compounds and the use of the compounds in the manufacture of medicaments for the treatment of pain, epilepsy, schizophrenia, neurodegenerative diseases and in particular Alzheimer's disease, Huntington's disease and Parkinson's disease, for the treatment of cerebral ischemia and infertility. , psychoses caused by increased amino acid levels, cerebral edema, conditions caused by one during administration to the central nervous system, especially in hypoxia and especially neonatal hypoxia and anoxia, for the treatment of AIDS-related dementia, encephalomyelitis, Tourette's syndrome, perinatal asphyxia, neuropathic pain, tinnitus, tinnitus respiratory diseases, cancer, cardiac arrhythmia, oral disorders and diseases, inflammatory conditions and diseases, renal failure, insomnia, stroke, thrombosis, urinary incontinence, diabetes, psoriasis, septic shock, cerebral trauma, leukemia and / or congestive heart failure. Pharmaceutical compositions containing the compounds are further described.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2001112197 DE10112197A1 (en) | 2001-03-14 | 2001-03-14 | Medicaments for treating e.g. epilepsy, schizophrenia, neurodegenerative diseases or especially pain, comprising new or known pyrazolo-pyrimidine or thiazolo-pyrimidine compounds |
DE2001153344 DE10153344A1 (en) | 2001-10-29 | 2001-10-29 | Medicaments for treating e.g. epilepsy, schizophrenia, neurodegenerative diseases or especially pain, comprising new or known pyrazolo-pyrimidine or thiazolo-pyrimidine compounds |
PCT/EP2002/002722 WO2002072585A2 (en) | 2001-03-14 | 2002-03-13 | Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034031D0 NO20034031D0 (en) | 2003-09-11 |
NO20034031L true NO20034031L (en) | 2003-10-21 |
Family
ID=26008763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034031A NO20034031L (en) | 2001-03-14 | 2003-09-11 | Substituted pyrazole and thiazole pyrimidines |
Country Status (25)
Country | Link |
---|---|
US (1) | US7135568B2 (en) |
EP (2) | EP1637533B1 (en) |
JP (1) | JP2004527508A (en) |
KR (1) | KR20030082982A (en) |
CN (1) | CN1318422C (en) |
AT (2) | ATE404568T1 (en) |
AU (1) | AU2002302419B2 (en) |
BR (1) | BR0208244A (en) |
CA (1) | CA2440760C (en) |
CY (1) | CY1105507T1 (en) |
CZ (1) | CZ20032474A3 (en) |
DE (2) | DE50207103D1 (en) |
DK (1) | DK1368355T3 (en) |
ES (2) | ES2263779T3 (en) |
HK (1) | HK1061034A1 (en) |
HU (1) | HUP0401211A3 (en) |
IL (2) | IL157895A0 (en) |
MX (1) | MXPA03008291A (en) |
NO (1) | NO20034031L (en) |
NZ (2) | NZ528639A (en) |
PL (1) | PL364388A1 (en) |
PT (1) | PT1368355E (en) |
RU (1) | RU2003129060A (en) |
SK (1) | SK11542003A3 (en) |
WO (1) | WO2002072585A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447100B2 (en) | 2002-08-26 | 2016-09-20 | Takeda Pharmaceutical Company, Ltd. | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ541836A (en) * | 2003-02-27 | 2008-12-24 | Palau Pharma Sa | Pyrazolopyridine derivatives |
GB0404434D0 (en) | 2004-02-27 | 2004-03-31 | Novartis Ag | Organic compounds |
WO2005112936A1 (en) * | 2004-05-14 | 2005-12-01 | The Regents Of The University Of Michigan | Compositions and methods relating to protein kinase inhibitors |
AR050188A1 (en) * | 2004-08-03 | 2006-10-04 | Uriach Y Compania S A J | CONDENSED HETEROCICLIC COMPOUNDS USED IN THERAPY AS INHIBITORS OF P38 KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP1736475A1 (en) * | 2005-06-21 | 2006-12-27 | Ferrer Internacional, S.A. | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates |
KR100838692B1 (en) | 2007-07-11 | 2008-06-16 | 한국화학연구원 | 7-(3',4'-dialkoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same |
WO2009093209A2 (en) * | 2008-01-24 | 2009-07-30 | Alla Chem, Llc | 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO [1,5-A]PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF |
EA017818B1 (en) * | 2008-01-24 | 2013-03-29 | Андрей Александрович ИВАЩЕНКО | SUBSTITUTED CYCLOALCANO[e OR d]PYRAZOLO[1,5-a]PYRIMIDINES - ANTAGONISTS OF SEROTONIN 5-HTRECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF |
WO2010041983A1 (en) * | 2008-10-06 | 2010-04-15 | Алла Хем, Ллс | Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof |
US20120135980A1 (en) * | 2008-12-22 | 2012-05-31 | Theodros Asberom | Gamma secretase modulators |
JO3407B1 (en) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | Tetrahydropyrazolopyrimidine Compounds |
CN102775412B (en) * | 2012-08-21 | 2013-05-01 | 四川大学 | Sedative and soporific compound, and preparation method and application thereof |
CN102977106B (en) * | 2012-12-12 | 2014-12-10 | 中国药科大学 | Kappa opioid agonist with peripheral analgesia effect |
CN105188694B (en) | 2013-03-15 | 2018-07-31 | 卓莫赛尔公司 | Sodium channel modulators for treating pain |
SG11201601367QA (en) * | 2013-09-10 | 2016-03-30 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
BR112019022465A2 (en) * | 2017-04-27 | 2020-05-12 | Takeda Pharmaceutical Company Limited | COMPOUND, MEDICINE, METHODS FOR ANTAGONIZING A CALCIUM SENSOR RECEIVER IN A MAMMALIAN AND TO PREVENT OR TREAT HEART FAILURE AND PULMONARY HYPERTENSION IN A MAMMALIAN, AND, USE OF THE COMPOUND. |
CN113354644B (en) * | 2020-03-04 | 2023-07-04 | 烟台药物研究所 | Pyrazolopyrimidine compound used as DPP-IV inhibitor and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264773A1 (en) | 1986-10-16 | 1988-04-27 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines |
US4847256A (en) * | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
ZA903588B (en) * | 1989-05-16 | 1991-02-27 | Merrell Dow Pharma | Excitatory amino acid antagonists |
GB9206266D0 (en) * | 1992-03-23 | 1992-05-06 | Merck Sharp & Dohme | Therapeutic agents |
FR2717812B1 (en) * | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Indeno [1,2-e] pyrazine-4-ones, their preparation and the drugs containing them. |
FR2722786B1 (en) * | 1994-07-20 | 1996-08-23 | Rhone Poulenc Rorer Sa | DERIVATIVES OF 4-HYDROXY-3-PHENYL-INDENO (1,2-B) PYRIDINE-2 (1H) - ONE, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM |
DE4444815A1 (en) * | 1994-12-15 | 1996-06-20 | Merck Patent Gmbh | Thienopyridone |
JP2003288537A (en) | 2000-09-25 | 2003-10-10 | Everyd.Com:Kk | System and method for article home delivery |
DE10112197A1 (en) | 2001-03-14 | 2002-09-19 | Gruenenthal Gmbh | Medicaments for treating e.g. epilepsy, schizophrenia, neurodegenerative diseases or especially pain, comprising new or known pyrazolo-pyrimidine or thiazolo-pyrimidine compounds |
-
2002
- 2002-03-13 KR KR10-2003-7011953A patent/KR20030082982A/en not_active Application Discontinuation
- 2002-03-13 ES ES02729998T patent/ES2263779T3/en not_active Expired - Lifetime
- 2002-03-13 RU RU2003129060/04A patent/RU2003129060A/en not_active Application Discontinuation
- 2002-03-13 DE DE50207103T patent/DE50207103D1/en not_active Expired - Lifetime
- 2002-03-13 CA CA2440760A patent/CA2440760C/en not_active Expired - Fee Related
- 2002-03-13 SK SK1154-2003A patent/SK11542003A3/en unknown
- 2002-03-13 MX MXPA03008291A patent/MXPA03008291A/en active IP Right Grant
- 2002-03-13 AT AT05026811T patent/ATE404568T1/en not_active IP Right Cessation
- 2002-03-13 JP JP2002571501A patent/JP2004527508A/en active Pending
- 2002-03-13 NZ NZ528639A patent/NZ528639A/en unknown
- 2002-03-13 HU HU0401211A patent/HUP0401211A3/en unknown
- 2002-03-13 PT PT02729998T patent/PT1368355E/en unknown
- 2002-03-13 CN CNB028096886A patent/CN1318422C/en not_active Expired - Fee Related
- 2002-03-13 DK DK02729998T patent/DK1368355T3/en active
- 2002-03-13 DE DE50212652T patent/DE50212652D1/en not_active Expired - Lifetime
- 2002-03-13 AU AU2002302419A patent/AU2002302419B2/en not_active Ceased
- 2002-03-13 ES ES05026811T patent/ES2311920T3/en not_active Expired - Lifetime
- 2002-03-13 EP EP05026811A patent/EP1637533B1/en not_active Expired - Lifetime
- 2002-03-13 EP EP02729998A patent/EP1368355B1/en not_active Expired - Lifetime
- 2002-03-13 AT AT02729998T patent/ATE328886T1/en not_active IP Right Cessation
- 2002-03-13 PL PL02364388A patent/PL364388A1/en not_active Application Discontinuation
- 2002-03-13 IL IL15789502A patent/IL157895A0/en unknown
- 2002-03-13 BR BR0208244-6A patent/BR0208244A/en not_active Application Discontinuation
- 2002-03-13 WO PCT/EP2002/002722 patent/WO2002072585A2/en active IP Right Grant
- 2002-03-13 NZ NZ540574A patent/NZ540574A/en unknown
- 2002-03-13 CZ CZ20032474A patent/CZ20032474A3/en unknown
-
2003
- 2003-09-11 NO NO20034031A patent/NO20034031L/en not_active Application Discontinuation
- 2003-09-11 IL IL157895A patent/IL157895A/en not_active IP Right Cessation
- 2003-09-12 US US10/660,794 patent/US7135568B2/en not_active Expired - Fee Related
-
2004
- 2004-06-09 HK HK04104154A patent/HK1061034A1/en not_active IP Right Cessation
-
2006
- 2006-07-05 CY CY20061100930T patent/CY1105507T1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447100B2 (en) | 2002-08-26 | 2016-09-20 | Takeda Pharmaceutical Company, Ltd. | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034031L (en) | Substituted pyrazole and thiazole pyrimidines | |
CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
WO2003053330A3 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3 | |
UA83899C2 (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
WO2006040451A2 (en) | Novel 9h-pyrido[2,3-b]indole derivatives serving as cdk and gsk3 inhibitors, method for the preparation thereof, and the pharmaceutical compositions containing such compounds | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
NO174772C (en) | Analogous procedure for the preparation of therapeutically active piperazinyl derivatives | |
MA32009B1 (en) | Novel derivatives of pyrazolo [3,4-d] pyrimidine as anticancer agents | |
ATE447571T1 (en) | PYRROLOÄ2,3-BUPYRIDINE DERIVATIVES THAT ACT AS KINASE INHIBITORS; METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
CA2811714A1 (en) | Imidazotriazinone compounds | |
ATE253918T1 (en) | USE OF HYMENIALDISINE AND ITS DERIVATIVES FOR THE PRODUCTION OF THERAPEUTIC AGENTS | |
WO2005097763A3 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
WO2005097762A3 (en) | 1,3,4-oxadiazol-2-ones as ppar delta modulators | |
AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
EP1958939A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
JP6532880B2 (en) | Hexahydrofuropyrrole as PDE1 inhibitor | |
CA2534529A1 (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
GEP20063960B (en) | New fluorinated benzothiadiazine, a process for their preparation and pharmaceutical compositions contained them | |
US11427590B2 (en) | Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases | |
WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
US11897876B2 (en) | Isoxazolidines as RIPK1 inhibitors and use thereof | |
WO2024040155A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |